The histological diagnosis of malignant mesothelioma in pleural biopsy specimens is a well recognised problem.1 Malignant mesothelioma may be indistinguishable from a reactive mesothelial cell proliferation, or from primary, or metastatic carcinoma. The same problem exists in the cytological diagnosis of serous fluids in which malignant mesothelioma cells may be difficult to differentiate from benign mesothelial cells or from metastatic carcinoma by morphological criteria alone.
Recent immunocytochemical studies of serous fluids have shown that monoclonal antibodies are useful in distinguishing benign from malignant cells. Human milk fat globule membrane antigen, carcinoembryonic antigen (CEA), and the Ca antigen have been shown in a wide variety of malignant epithelial cells but have rarely been seen in reactive mesothelial cells.2`4 A previous study on histological samples of mesothelium reported similar findings with two antibodies against human milk fat globule membrane antigen and an anti-CEA antiserum.5
In the present study a panel of seven monoclonal antiepithelial antibodies of different specificities, including anticytokeratin, human milk fat globule Accepted for publication 9 July 1986 membrane, Ca and carcinoembryonic antigen were evaluated to determine whether they could distinguish between reactive and malignant mesothelial cells and lung carcinoma in histological preparations, using an immunoalkaline phosphatase staining method.
Material and methods

SAM PLES
All tissues were obtained from the surgical pathology files of the histopathology department, John Radcliffe Hospital, Oxford and had been fixed in 10% unbuffered formalin and embedded in paraffin. Cases had been classified according to conventional histological criteria. Samples studied comprised: seven pleural mesotheliomas (most of which were referred to and accepted by the Pneumoconiosis panel); 15 primary lung tumours, which included four squamous cell carcinomas, four adenocarcinomas, five oat cell and two carcinoid tumours; and reactive mesothelial cells from seven cases of recurrent pneumothorax. The lung tumours were selected as representative paraffin embedded specimens from a series of 54 lung tumours previously studied in cryostat sections.6 The samples of benign mesothelial cells were selected from Gatter et al'°a ntigen (CEA) a large number of cases as clear cut examples of reactive mesothelium. Cases in which any possible confusion might be made with underlying pulmonary tissue were excluded. Table 1 gives details of the monoclonal antibodies used in this study. Sections (5 gm) were stained by the APAAP immunoalkaline phosphatase staining method, as described previously.'3 Prior trypsinisation of sections was not performed.
IMMUNOCYTOCHEMISTRY
Results
REACTIVE MESOTHELIUM
Monoclonal antibody KLI (anticytokeratin) reacted with mesothelium in all seven benign cases. It characteristically stained the single layer of cuboidal mesothelial cells lining the pleural surface with a strong cytoplasmic and surface reaction (figs la, 2a). Areas that contained clumps or multilayers of plump reactive mesothelial cells, either on the pleural surface or exfoliated, also reacted strongly with KLI Antibodies E29 and HMFG2 (antiepithelial membrane antigen) and the three Ca antibodies gave similar staining reactions to each other. Three of the seven benign cases showed positive staining with these antibodies. In these cases the single cuboidal layer of mesothelial cells showed both cytoplasmic and surface staining (figs lb, c). In areas in which there were multilayers of reactive mesothelial cells these were usually negatiye (fig 2b) , although the occasional exfoliated mesothelial cell was positive with these five antibodies. Two cases had clefts lined by reactive mesothelial cells that were strongly positive ( the other hand, using wet fixed cytological material, Immunohistological studies with polyclonal anti-did not detect HMFG2 on benign mesothelial cells. sera against keratins of different molecular weights Although these differences could be due to different have shown that mesotheliomas and benign meso-techniques and fixatives used, a study comparing thelium express a 63 kd keratin not detected in most different staining and fixation methods on the same lung carcinomas.20 Such a difference in staining for specimens showed that the HMFG2 determinant was this 63 kd keratin between mesothelioma and ade-occasionally expressed on reactive mesothelial cells.2' nocarcinoma may have diagnostical application, and These previous reports indicated that mesothelial further work, particularly with specific monoclonal cells could express the HMFG2 determinant. The antikeratin antibodies, should be undertaken to clar-present study has shown the presence of HMFG2 in ify these results.
reactive mesothelium in three of seven cases. This is in Both monoclonal antibodies (HMFG2 and E29) to contrast to the findings of Marshall et al,S who the human milk fat globule membrane antigen (anti-observed focal staining with HMFG2 in only one of EMA) reacted with all cases of mesothelioma. Three 13 cases of reactive mesothelium. These workers used Table 3 Immunohistological results ofpanel of monoclonal antibodies with lung carcinoma group.bmj.com on December 18, 2017 -Published by 24 Ghosh, Gatter, Dunnill, Mason an immunoperoxidase technique and trypsinised their tissue. Marshall et al5 detected the HMFG2 determinant in mesothelioma and lung carcinoma and suggested that positive staining with this antibody indicates malignancy, while negative staining is more likely to be benign rather than malignant mesothelium. Our findings, however, differ from this and indicate that a positive reaction cannot be used to distinguish a benign from malignant condition.
The three monoclonal antibodies directed against different determinants on the Ca antigen gave similar staining reactions and were positive with three of seven cases of reactive mesothelium, all the mesotheliomas, and most of the carcinomas. Positive reactions of these three antibodies with mesothelioma cells in cytological preparations have been noted. (AK Ghosh, unpublished observations).2 3 12 The reactions of the antibodies on benign mesothelial cells in cytological preparations have differed. Cal was weakly expressed on mesothelial cells in two of 47 benign effusions (combined data from two series).23 Ca2 was not detected on reactive mesothelial cells, while Ca3 was detected in benign mesothelial cells in eight of 23 cases.12 These latter findings suggest that the antigenic determinant recognised by at least two of the Ca antibodies is variably present on mesothelial cells.
A previous immunohistological study of pleural biopsy specimens detected Cal in four of eight cases of benign mesothelium, seven of 12 cases of mesothelioma, and three of five cases of metastatic car-22 cinoma. Our findings are consistent with these observations and iidicate that these antibodies do not distinguish between malignant and benign mesothelium in histological sections.
CEA was absent in all cases of mesothelioma and reactive mesothelium, but was present in most cases of carcinoma, both here and in a previous study of 54 lung tumours, which included cryostat sections from the present cases.6 These findings agree with our observations on cytological samples where we found that CEA was absent from benign mesothelial cells, weakly expressed in one case of mesothelioma (subsequent cases of mesothelioma have been negative, AK Ghosh, unpublished observations), and present in 80% of carcinomas. 2 Previous immunohistological studies of CEA in mesothelioma have given conflicting results, with some showing no staining5 23 24 and others positive staining.'5 16 Different staining techniques, the use of trypsin, and differing polyclonal antisera could account for these differences. Whether or not the monoclonal or polyclonal antibodies react with nonspecific crossreacting antigen may also be important (the monoclonal anti-CEA used here does not react).
There have only been three histological studies using polyclonal CEA antisera on reactive mesothelium in which no staining was observed.5 15 24 Our results are in agreement with these findings. The reactions of the monoclonal CEA in this study with lung carcinomas were similar to those observed by Gatter et al6 using the same reagent: most of these tumours showed positive staining. Other workers have detected CEA in lung tumours, particularly in bronchial adenocarcinomas.5 16 17 24 The difference in CEA staining in mesotheliomas and carcinomas makes it a useful marker for differentiating these two neoplasms. A positive reaction with CEA suggests carcinoma and makes a diagnosis of mesothelioma unlikely. A distinction cannot be made (at least with the antibody used in this study), however, between mesothelioma and reactive mesothelium, or between the different histological types of lung carcinoma.
At present there are no reagents that can conclusively distinguish benign from malignant mesothelium. Although monoclonal antibodies to milk fat globule and Ca determinants can help to make this distinction in cytological preparations, our findings in histological preparations are less helpful. The location of positive staining or intensity does not help to make this distinction, as cases of benign mesothelium exhibited strong staining, especially in cleft like areas of cells. This was a feature also observed in mesothelioma. More specific markers for mesothelioma will therefore be required to facilitate their histological diagnosis.
